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 Use of anti-CD163-dexamethasone is an attractive strategy for anti-inﬂammatory treatment.
 In the present study the impact of anti-CD163 dexamethasone on liver regeneration in rats was studied.
We show that low dose anti-CD163 dexamethasone has no negative effect on liver regeneration after 70% hepatectomy in rats. Characters should then
be down to 122.
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a b s t r a c t
Introduction: Surgical resection is the gold standard in treatment of hepatic malignancies, giving the
patient the best chance to be cured. The liver has a unique capacity to regenerate. However, an in-
ﬂammatory response occurs during resection, in part mediated by Kupffer cells, that inﬂuences the speed
of regeneration. The aim of this study was to investigate the effect of a Kupffer cell targeted anti-
inﬂammatory treatment on liver regeneration in rats.
Methods: Two sets of animals, each including four groups of eight rats, were included. Paired groups from
each set received treatment with placebo, low dose dexamethasone, high dose dexamethasone or low dose
anti-CD163 dexamethasone. Subsequently, the rats underwent 70% partial hepatectomy. The two sets were
evaluatedonpostoperativeday2or5, respectively. Bloodwasdrawn for circulatingmarkersof inﬂammation
and liver cell damage; liver tissue was sampled for analysis of regeneration rate and proliferation index.
Results: The high dose dexamethasone group had signiﬁcantly lower body and liver weight than the
placebo and anti-CD163-dex groups. There were no differences in liver regeneration rates between
groups. Hepatocyte proliferation was completed faster in the placebo group, although this was not
signiﬁcant. The anti-CD163-dex group showed increased blood levels of albumin and alanine amino-
transferase and a diminished inﬂammatory response in terms of signiﬁcantly reduced haptoglobin, a2-
macroglobulin and Interleukine-6.
Conclusion: Low dose dexamethasone targeted to Kupffer cells does not affect histological liver cell
regeneration after 70% hepatectomy in rats, but reduces the inﬂammatory response judged by circulating
markers of inﬂammation.
© 2015 The Authors. Published by Elsevier Ltd on behalf of IJS Publishing Group Limited. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
The liver has a striking regenerative capacity after hepatic
resection. Postoperative regeneration is mediated through an
orchestrated proliferation of hepatocytes (not involving stem cells),
resulting in enlargement of the residual liver lobes with restoration
of liver mass [1]. This process is carried out at the same time as the
liver maintains support for body homeostasis [1].
Surgical resection or transplantation, are the only potentially
curative treatment options for most cases of hepatic malignancy
[2]. Thus, the possible demand for therapeutic hepatectomy is
enormous. For example, colorectal cancer is the third most preva-
lent cancer in the world [2]. Almost half of these patients will
develop colorectal liver metastases during the course of their dis-
ease [3e5]. Untreated, their median survival is only 10 months [4],
whilst 5-year survival is very rare [3,6]. Similarly, primary liver
cancer (in most cases hepatocellular carcinoma) is globally the
second most frequent cause of cancer death in men [7]. Again,
surgery remains the only curative treatment for most cases.
Perioperative blood loss and transfusion requirements are fac-
tors known to be associated with the degree of morbidity and
mortality following hepatic resection [8,9]. Vascular occlusion
techniques such as Pringle's maneuver may be used in an attempt
to limit hemorrhage [9]. However, the ischemic effect of this type of
maneuver may induce a harmful inﬂammatory response known as
ischemia-reperfusion (IR) injury [9,10].
From previous studies, Kupffer cells are known to be involved in
the activation of cell division during the process of liver regenera-
tion by the production of tumor necrosis factor (TNF)-a and inter-
leukin (IL)-6 [1,11,12]. However, Kupffer cells are also known to be
mediators of IR injuries [13e15].
Considerable research has been conducted on different ap-
proaches toenhance liver survival andviabilityafter resection [9,12].
Focus has mainly been on surgical procedures such as ischemic
conditioning [16] and intermittent clamping [17]. However more
recently, attention has been directed at pharmacological strategies
and positive results have been reported suggesting a protective ef-
fect of treatment with sevoﬂurane [18] and with prednisolone
[19,20]. Against this backing, a possible new strategy could be anti-
inﬂammatory therapy with the novel reagent anti-CD163-mAb
conjugated PEGylated liposomes [21] that can be loaded with
dexamethasone to form anti-CD163-dex-lipo. Anti-CD163-dex-lipo
is directed against the CD163 receptor. CD163 is a hemoglobin
scavenger receptor, highly expressed on macrophages in the liver,
spleen and bone marrow, and at sites of inﬂammation [22].
Previously, it has been shown that anti-CD163-dex constructed
as an antibody-drug conjugate (ADC) inhibits the inﬂammatory
response of rat macrophages after injection with lipopolysaccha-
rides (LPS) [22]. In addition, we showed that anti-CD163-dex ADC
protects against IR injury after liver ischemia by inhibiting
apoptosis [23]. The aim of the present study was to investigate the
possible effect of Kupffer cell targeted anti-inﬂammatory treatment
with anti-CD163-dex liposomes on liver regeneration in rats after
partial hepatectomy (PHx).
2. Material and methods
2.1. Animals and ethics
All animal experiments were performed under the approval of
Danish Animal Experiment Inspectorate, Copenhagen, Denmark
(license number 2012-15-2934-00591 expansion), and in accor-
dance with the Guide for the Care and Use of Laboratory Animals
published by the National Institute of Health, USA [24]. MaleWistar
rats of 200 g, corresponding to an age of app 50 days, were obtained
from Taconic Biosciences (Borup, Denmark) and were acclimatized
for one week prior to operation. The animals were housed in
standard animal laboratories with the temperature maintained at
23 C, an artiﬁcial 12 h light-dark cycle, and free access to food
(Altromin) and water. The rats were daily monitored with regard to
weight, behavior and physical appearance by veterinary nurses and
the ﬁrst author. All animals were daily scored by humane endpoint
with ‘General Distress Score’ as described by Lloyd andWolfensohn
[25]. Brieﬂy the rats were evaluated on the following endpoint:
Appearance; Food and water intake; Clinical signs; Natural
behavior and Provoked behavior. If a score of 2 was observed in any
parameter the animals were even closer observed and attended to
at minimum 8th hour intervals. If the condition was not remedied
during 24 h the rat was euthanized by cervical dislocation. If a score
of 3 was observed in any parameter the animals were euthanized
immediately. Dead rats were autopsied to establish the cause of
death. The species, sex and size/age, was chosen based on previous
experience in the research group regarding studies in liver regen-
eration in rats [26,27].
2.2. Experimental design
2.2.1. Design
Sixty-four rats were given treatment, underwent 70% PHx, and
were evaluated on postoperative day (POD) 2 or 5 (Fig. 1). The
choice of evaluation days was based on a previously conducted
study, which showed day 2 and 5 to be key points in rat liver
regeneration [26].
2.2.2. Treatment
With the operator blinded to treatment, the animals were block
randomized into four groups. They received either 1) placebo
(phosphatebuffered saline), 2) lowdosedexamethasone-phosphate
(LDD; 0.2 mg/kg), 3) high dose dexamethasone phosphate (HDD;
1.0 mg/kg), or 4) Anti-CD163-mAb conjugated liposome-
encapsulated low dose dexamethasone-21-hemisuccinate (anti-
CD163-dex; 0.2 mg/kg). The synthesis of anti-CD163-liposomes has
been described previously [21] and remote loading with dexa-
methasone-21-hemisuccinate was performed as described in Ref.
[28]. The conjugate was administrated by intravenous injection
(2 ml/kg) to the tail vein 18 h before liver resection. For animals
evaluated on POD 5, an additional dose of treatment was given at
POD 2. The doses used in the present study, were based on experi-
ence from earlier studies conducted on dexamethasone and anti-
CD163-dexamethasone [22,29].
2.2.3. Anesthetics and analgesia
General anesthesia with sevoﬂurane was used during adminis-
tration of treatment, surgical procedures and at euthanisation. The
animals were anesthetized in an induction chamber with a mixture
of oxygen (2.0 L/min), N2O (0.5 L/min) and 4% sevoﬂurane (Forene;
Abbott Laboratories, Maidenhead, UK). During procedures, anes-
thesia was maintained with 3% sevoﬂurane in oxygen and N2O as
described above, which was administered through a mask covering
the face of the rat. Before surgery, the animals were given a sub-
cutaneous injection of a long-lasting non-steroid anti-
inﬂammatory drug, 5 mg/kg Carprofen (RimadylVet; Pﬁzer Ani-
mal Health, Exton, USA) and 2.5 ml of isotonic saline. Injection of
analgesics was repeated on POD 1, 2, and 3.
2.2.4. Surgical procedure
The animal was placed in a supine position on a temperature
controlled heating pad, a midline abdominal incisionwasmade and
the liver was mobilized. PHx was performed as ﬁrst described by
Higgins and Anderson [30]. In brief, the median and left lateral lobes
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of the liver were ligated and the lobes were resected, resulting in
70% liver resection. The abdominal wall was then closed with a 4e0
absorbent suture and the skin closed with agraffes.
2.2.5. Evaluation
After PHx, the rats were again block randomized, this time into
two sets of four treatment groups for evaluation on either POD 2 or
5. On the given POD, the rats were anaesthetized, blood samples
were collected from the heart by cannulation and they were then
euthanized by cervical dislocation. The regenerated liver was
removed, weighed and the caudate liver lobe used for histological
assessment.
2.3. Biochemical analysis
Blood was sampled from the heart at euthanisation, processed
and stored at80 C until analysis. Alanine aminotransferase (ALT),
aspartate aminotransferase (AST), alkaline phosphatase (ALP),
bilirubin, albumin and haptoglobin levels were measured using
Cobas 6000 (Roche Diagnostics, Hvidovre, Denmark). Serum levels
of IL-6 and TNF-a were determined using commercial enzyme-
linked immunosorbent assays (ELISAs; Life Technology, Naerum,
Denmark). Rat acute phase protein alpha-2-macroglobulin (a2M)
was detected using a quantitative ELISA-based test kit (Consultants
Laboratory, Portland, USA). All assays were performed as speciﬁed
by the manufacturers' instructions.
2.4. Liver weight and regeneration rate
The change in liver weight was evaluated as the hepatic
regeneration rate (RR). RR was deﬁned as: liver weight per 100 g of
body weight at euthanisation divided by preoperative calculated
liver weight per 100 g of body weight multiplied by 100
RR ¼

LWm
100gBW

sac

LWc
100gBW

pre
$100
LWm is the measured liver weight at euthanasia and LWc is the
preoperative calculated liver weight. The preoperatively estimated
total liver weight was calculated from the resected liver weight.
After removing 70% liver tissue the LWc was estimated as 100%:
LWC ¼ (Weight of 70% rec/70) x 100.
2.5. Histological evaluation
2.5.1. Tissue preparation
For histological evaluation the caudate liver lobe was ﬁxed in
phosphate-buffered 4% formaldehyde, cut into 2 mm parallel slabs
using a tissue slicer, and embedded in parafﬁn. A 30-mmsectionwas
cut from each of the parafﬁn-embedded blocks for immunohisto-
chemical staining.
2.5.2. Immunohistochemistry
Hepatocellular proliferation was estimated using immunohis-
tochemical staining for the Ki-67 antigen. Ki-67 is expressed during
all active phases of the cell cycle (G1, S, G2 andM phases), but not in
resting (G0) cells [31]. Immunohistochemical staining of the 30-mm
parafﬁn sections was performed on an automatic stainer using a
standard (in-house) protocol, modiﬁed for use in thick sections, as
described previously [26]. In brief, following epitope retrieval the
sections were stained with monoclonal mouse anti-rat Ki-67 spe-
ciﬁc antibody (Dako, Glostrup, Denmark), bound antibody was
detected and positive signals visualized by using the EnVisionþ
horseradish peroxidase labeled anti-mouse detection system
(Dako), and the sections were counterstained with hematoxylin.
2.5.3. Stereological quantitation
Stereological methods were applied to quantify the number of
proliferating hepatocytes in the immunohistochemically stained
sections [32]. The liver sections were prepared according to ste-
reological principles using systematic uniform random sampling
(SURS) [33,34]. All sections were analyzed using the Olympus BH-
50 microscope with a 60x oil objective lens. The microscope was
modiﬁed for stereology with a motorized stage and a digital camera
connected to a PC with newCAST 3.6.5.0 software (Visiopharm,
Hørsholm, Denmark). This gave a magniﬁcation of 3014x. The same
investigator analyzed all sections and was blinded to the treatment
group.
Fig. 1. Flowchart. The ﬂowchart of the experiment.
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The optical fractionator method [35,36] was used to assess the
total number of Ki-67-positive cells in each rat liver. Approximately
0.5% of the section area was analyzed for Ki-67-positive cells and
the thickness of the sampled section was measured every time a
positive cell was seen in the frame. The number of Ki-67-positive
cells N was calculated using the following equation:
N ¼ 1
SSF
$
1
ASF
$
1
HSF
$
X
Q
SSF is the Section Sampling Fraction ¼ t=T , t is the height of the
sampled section cut on a calibratedmicrotome (30 mm), and T is the
average thickness of the embedded slabs following shrinkage. The
thickness of the slabs was 2mmbefore embedding. Several of these
were exhaustively cut in thin histological slices to measure slab
thickness after shrinkage. Seven tissue landmarks for these slabs
were followed through the whole series of sections and the average
slab thickness after shrinkage was calculated:
T ¼ ð1510þ 1570þ 1585þ 2005þ 2080þ 1885
þ 1850Þ mm=7
¼ 1784 mm
ASF is the Area Sampling Fraction ¼ aðframeÞdx $dy , a(frame) is the area
of the 2D unbiased counting frame, 7500 mm2, and dx and dy are
the stepping distance in the x- and y-direction equal to 1225 mm,
respectively.
HSF is the Height Sampling Fraction ¼ ht ðQÞ, where h is the
disector height (15 mm) and t(Q) is the number(Q) weighted
mean section thickness (¼15/28.32).
Q-is the number of positive cells counted. The counting rules
used are described in Fig. 2.
2.6. Statistical analysis
All statistical analyses were performed in SPSS 20 for Windows
(SPSS Inc., Chicago, Illinois, USA). Data were presented as mean
(±standard error (SE)) and p-values < 0.05 considered signiﬁcant.
To determine if there were any signiﬁcant differences between the
groups, a one-way ANOVA test was performed when applicable.
One-way ANOVA was considered applicable if data met the as-
sumptions of no outliers, were normally distributed and had ho-
mogeneity of variances. Nonparametric data were tested by
KruskaleWallis test followed by ManneWhitney U test.
3. Results
3.1. Mortality
Ten animals died before evaluation; three from the placebo
group (two from infection and one from an unidentiﬁable cause),
two in the LDD group (from infection), four in the HDD group (from
infection), and one in anti-CD163-dex group (as a consequence of
wound rupture resulting in intestinal perforation).
3.2. Body weight
The animals had a mean body weight of 202 g (191e217 g)
before medication and surgery. In the HDD group, there was a
steady decline in body weight throughout the experiment, this
being signiﬁcantly lower at all time points compared with the
placebo (before res p < 0,0005; POD2 p ¼ 0.008; POD5 p ¼ 0.001)
and to the anti-CD163-dex (before res p < 0.002; POD2 p ¼ 0.003;
POD5 p ¼ 0.004) groups (Fig. 3a). On POD 2, the anti-CD163-dex
group was signiﬁcantly heavier than the LDD group (p ¼ 0.012)
(Fig. 3a). On POD 5, the body weight was also signiﬁcantly lower in
the HDD group compared with the LDD group (Fig. 3a).
3.3. Liver weight
The average removed liver weight was 6.26 g (5.26e7.30 g)
(mean of all groups on resection time, 18 h after treatment). The
mean liver weight of the HDD group was signiﬁcantly lower than
the placebo group on POD 5 (p ¼ 0.002) (Fig. 3b).
3.4. Liver regeneration rate
On POD 2, there was a trend towards a lower regeneration rate
in the HDD group compared with the placebo group. However this
difference was not signiﬁcant (p ¼ 0.062). Otherwise, regeneration
rates were comparable between the groups (Fig. 4).
3.5. Hepatocyte proliferation
There were no signiﬁcant differences in the hepatocyte prolif-
eration between the groups on POD 2 (Fig. 5). On POD 5, the pro-
liferation was signiﬁcantly lower in the placebo group compared
with the anti-CD163-dex (p ¼ 0.015) and LDD (p ¼ 0.015) groups
(Fig. 5).
3.6. Biochemistry
On POD 2, ALP was signiﬁcantly lower in the HDD group
compared with the placebo group (p ¼ 0.042) (Table 1). On POD 5,
ALT was signiﬁcantly higher in the anti-CD163-dex group
compared with placebo (p ¼ 0.038) and albumin was signiﬁcantly
higher in the anti-CD163-dex group compared with the HDD group
(p ¼ 0.02) (Table 1). On POD 5, haptoglobin (p ¼ 0.02), a2M
(p¼ 0.038) and IL-6 (p¼ 0.038) were signiﬁcantly lower in the anti-
CD163-dex group compared with the HDD group (Table 1). In
addition, a2M was signiﬁcantly lower in the anti-CD163-dex group
compared with the placebo group (p ¼ 0.028) on POD5 (Table 1).
Fig. 2. Immunohistochemical staining of liver section for Ki-67 proliferation an-
tigen, including counting frame. The counting frame (100  75 mm) consists of in-
clusion lines (green lines seen to the right and in the upper part of the frame) and
exclusion lines (red lines to the left and in the lower part of the 2D frame, together
with lines at the top and bottom of the disector height). Positively stained hepatocytes
were counted if their nuclei were in focus inside the counting frame or if they touched
an inclusion line, and did not touch the exclusion lines. Seven Ki-67 positive hepato-
cytes (marked with A's) can be seen in this frame.
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4. Discussion
We investigated the possible effect of a Kupffer cell targeted
anti-inﬂammatory treatment on liver regeneration in rats. Our
study found that treatment with the low dose antibody conjugate
anti-CD163-dex before PHx had no apparent effect on histological
post-resection liver regeneration, compared with controls treated
with other regimens or placebo. These results require further
testing in future studies. However, they suggest that anti-CD163-
dex treatment may be applied without undue concern that the
antibody conjugate might be associated with undesirable anti-
proliferative effects on the liver after resection.
Kupffer cells are believed to be the principal source of cytokine
release after PHx. Cytokines are key mediators that may initiate,
modulate, or suppress liver regeneration after hepatectomy
[13e15,37]. However, there is also strong evidence that they play a
central role in triggering the undesirable inﬂammatory reactions
involved in IR injury. Use of anti-CD163-dex is an attractive strategy
for anti-inﬂammatory treatment, as it may allow the speciﬁc de-
livery of a localized anti-inﬂammatory effect targeted through the
Fig. 3. a. Body weight. The dynamics in body weight. Mean (±SE). Signiﬁcant differences have been indicated with symbols. Before resection day 0: HDD vs. placebo (*p < 0,0005)
and HDD vs. anti-CD163-dex (**p ¼ 0.002). At POD 2: HDD vs. placebo (*p ¼ 0.008); HDD vs. anti-CD163-dex (**p ¼ 0.003) and anti-CD163-dex vs LDD (#p ¼ 0.036). At POD 5: HDD
vs. placebo (*p ¼ 0.001), HDD vs. anti-CD163-dex (**p ¼ 0.004) and HDD vs. LDD (***p ¼ 0.012). b. Liver weight. The dynamics in liver weight. Mean (±SE). Signiﬁcant differences
have been indicated with symbols. POD 5: HDD vs. placebo (*p ¼ 0.002).
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macrophage-speciﬁc CD163 receptor, whilst potentially avoiding
the often, serious systemic effects of high-dose glucocorticoids.
We found no differences in either liver weight or regeneration
rates comparing rats treated with placebo or with anti-CD163-dex,
on either POD 2 or POD 5. In a previous study, Meijer et al. used
experimental administration of clodronate-loaded liposomes
(CI2MDP) to deplete cytokines through the complete physical
elimination of Kupffer cells [37]. This led to inhibition of liver
regeneration, as judged by regeneration rate. Moreover, Meijer et al.
showed that CI2MDP treatment inhibited hepatocyte DNA synthe-
sis in the regenerating liver, as determined by the hepatocyte
bromodeoxyuridine (BrdU) labeling index. Given the evidence that
Kupffer cell activation is important in post-resection hepatocyte
proliferation the present and the study by Meijer et al. are in
agreement as anti-CD163-dex did not totally abolish the cytokine
response as did CI2MDP treatment [37]. We found a signiﬁcant
higher hepatocyte proliferation in the LDD group compared to
placebo, but no signiﬁcant difference between the placebo and the
HDD group. The latter was probably due to a higher variance in the
HDD group than the LDD group regarding this parameter.
Tsutsumi et al. studied the effect of selective inhibition of TNF-a
and IL-6 on liver regeneration in rats receiving a 90% hepatectomy.
In contrast to Meijer et al. [37], Tsutsumi et al. found that sup-
pression of cytokines (TNF-a and IL-6) stimulated liver regenera-
tion as judged by proliferating cell nuclear antigen (PCNA) and by
remnant liver weight [38]. They also demonstrated improved
Fig. 4. (aþb). Regeneration Rate. The regeneration rate on POD 2 and POD 5. Mean (±SE).
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survival in the group of rats undergoing suppression of cytokine
production. A possible explanation for this apparent discrepancy
could be that Tsutsumi el al. performed their studies in rats
following a 90% liver resection, in contrast to the 70% liver resection
used by Meijer et al. It is possible, that different intracellular
pathways might be turned on or off, depending on the amount of
liver resected. Glanemann et al. investigated the effect of preop-
erative administered systemic methylprednisolone (MP) in
partially hepatectomised rats [39]. They showed that MP tended to
be associated with lower liver weights, but had no apparent impact
on the remnant liver to body weight ratio [39], results that are
similar to our ﬁndings with HDD in the present study. With regard
to proliferative activity, Glanemann et al. found no signiﬁcant dif-
ferences comparing MP and placebo treated rats, as assessed by
mitotic index, by percentage of Ki-67 positively immunostained
hepatocytes, and by cyclin-D1 expression [39]. In this regard, their
results are in agreement with our ﬁndings in the present study. A
common feature of the experimental strategy in the studies dis-
cussed here, that investigated proliferation, was that this was
assessed by semi-quantitative methods [37e39]. As discussed later,
Fig. 5. (aþb). Hepatocyte proliferation. The hepatocyte proliferation on POD 2 and POD 5. Mean (±SE). Signiﬁcant differences have been indicated with symbols. POD 5: Placebo vs.
LDD (*p ¼ 0.015) and placebo vs. anti-CD163-dex (**p ¼ 0.015).
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this strategy is associated with several potential pitfalls [33].
During hepatic resection, it is important to reduce blood loss
that requires transfusion, since this is known to have a negative
impact on postoperative morbidity and mortality [8,40]. Vascular
occlusion, for example by Pringles maneuver, is a frequently used
method to minimize blood loss [41]. However, this causes IR in-
juries to the liver [9]. In a previous study we showed that anti-
CD163-dex treatment in rats protected against development of
apoptosis after IR injuries [23]. Thus we can speculate, on the basis
of our present results, that anti-CD163-dex could reduce IR injuries
without inﬂuencing liver regeneration and may, therefore, be a
good candidate for pharmacological preconditioning.
Body weight loss is a strong marker of general distress in ani-
mals [42]. In this study, rats in the HDD group had a signiﬁcant fall
in body weight throughout the study. On the other hand, anti-
CD163-dex treated rats showed an increase in body weight com-
parable with placebo, and had fewer complications in terms of
infections than HDD treated animals. In a study by Graversen et al.,
anti-CD163-dex as an ADC had no major systemic effects as
measured by reduction in thymus, spleen, or total body weight,
whereas this was observed after systemic HDD [22]. This suggests
that by targeting dexamethasone to macrophages, one may be able
to avoid the side effects seenwith systemic administration, and that
the effect is also observed using targeted liposomes loaded with
dexamethasone.
ALT has been widely used as a biochemical marker of hepatic
injury [43]. POD 2 ALT levels were lowest in the anti-CD163-dex
group, although there were no signiﬁcant differences between
groups. However, ALT was signiﬁcantly higher in the anti-CD163-
dex group compared with placebo on POD 5. As ALT has a half-
life around 47 h, the surgical stress to the liver is expected to
result in elevations in ALT levels primarily within the ﬁrst two days
[26,43]. The unexpected results found in the present study may, of
course, have occurred by chance. An alternative explanation could
be that anti-CD163-dex treatment resulted in increased damage to
hepatocytes. However, this conclusion would contrast with the
ﬁndings of a separate study by our group, in which we were unable
to demonstrate a protective effect of anti-CD163-dex treatment on
hepatocyte apoptosis after IR injury [23]. A third alternative
explanation could be that anti-CD163-dex treatment delays
apoptosis inmany hepatocytes injured by surgery, since levels were
lower (although this did not reach signiﬁcance) in this group on
POD 2.
Albumin is an established marker of the hepatic ability to
synthesize proteins [43]. In the present study, the anti-CD163-dex
group had signiﬁcantly higher albumin levels compared with the
HDD group. Glanemann et al. also showed that rats treated with
systemic MP had signiﬁcantly reduced albumin levels [39]. This
underlines the difference between systemic and macrophage tar-
geted corticosteroids, i.e. systemic treatment impairs albumin
synthesis by the liver.
The inﬂammatory response to surgical stress is known to cause
a rise in acute phase proteins such as haptoglobin and a2M [26,44].
Blood levels of haptoglobin and a2Mwere signiﬁcantly lower in the
anti-CD163-dex group compared with HDD, consistent with a
reduced inﬂammatory response in the liver. A postoperative rise in
IL-6 has been associated with IR injuries and adverse patient
outcome [13,45]. In our study, anti-CD163-dex signiﬁcantly
reduced levels of IL-6 compared with HDD. The fact that anti-
CD163-dex attenuated the cytokine response indicates its anti-
inﬂammatory potency and potential protection against IR injuries.
Both in a rat and a porcine LPS-model, anti-CD163-dex has been
shown to have an anti-inﬂammatory effect in terms of reduced
cytokines, comparable with ﬁfty times higher concentrations of
free dexamethasone [22,46].
The speciﬁc expression of CD163 in macrophages makes it an
interesting therapeutic target, opening up the possibility of
directing a speciﬁc effect restricted to localized sites of inﬂamma-
tion such as are seen following PHx [47]. The anti-inﬂammatory
action of anti-CD163-dex may also be of interest in the future
treatment of toxic and autoimmune liver disorders such as AHH,
primary biliary cirrhosis, autoimmune hepatitis, and primary
sclerosing cholangitis. By using a locally active treatment, it may be
possible to reduce or abolish the complications seen after long-
term therapy with high-dose corticosteroids. However, these pos-
sibilities must be the subject for future research.
A strength of the present study is our use of design-based
stereological methods in the histological evaluation. Unlike the
semi-quantitative methods used in most other studies, stereology
makes use of randomization to ensure that the analyzed part of
the tissue is representative of the whole structure [33]. This allows
quantitative data to be collected in an unbiased way, reducing the
subjectivity that is an integral part of non-stereological tech-
niques. Furthermore, it takes tissue shrinkage into account in an
unbiased fashion [33,36]. A limitation of the study might be the
relatively small number of animals in each group (n ¼ 8). A small
number gives a risk of overlooking an actual difference between
the groups.
Table 1
Biochemistry and cytokines.
Liver biochemistry POD 2 POD 5
Placebo LDD HDD AD Placebo LDD HDD AD
ALT (U/I) 127.74 (13.46) 122.59 (12.65) 127.86 (11.69) 111.89 (15.52) 32.40 (4.71) 34.54 (4.23) 37.00 (4.61) 49.68 (5.35) *p 0.038
AST (U/I) 254.93 (19.28) 256.49 (28.10) 243.83 (26.99) 211.91 (30.34) 84.59 (4.94) 85.78 (5.71) 105.45 (11.43) 145.95 (32.00)
ALP (U/I) 496.25 (18.48) 498.88 (51.29) 401.00 (25.30)
#p 0.042
498.75 (28.88) 229.50 (9.46) 230.63 (20.79) 250.25 (23.74) 218.25 (10.51)
Albumin (g/l) 9.90 (0.48) 9.63 (0.30) 10.48 (0.42) 9.59 (0.62) 9.62 (0.95) 10.31 (1.09) 9.33 (0.45) 11.24 (0.57)**p 0.020
Bilirubin (mmol/I) 4.61 (0.65) 4.61 (0.36) 4.51 (0.94) 4.38 (0.54) 0.85 (0.16) 0.88 (0.09) 1.05 (0.24) 1.08 (0.09)
Haptoglobin (g/l) 0.262 (0.029) 0.254 (0.046) 0.303 (0.030) 0.299 (0.043) 0.572 (0.075) 0.519 (0.079) 0.649 (0.039) 0.386 (0.040)**p 0.020
Cytokine proﬁle POD 2 POD 5
Placebo LDD HDD AD Placebo LDD HDD AD
TNF-a (pg/ml) 6.56 (2.23) 5.53 (1.33) 8.87 (4.96) 29.30 (25.26) 4.71 (1.76) 1.37 (1.05) 4.37 (2.15) 1.37 (0.63)
a2-macro- globulin
(mg/ml)
583.37 (150.53) 617.49 (107.62) 744.89 (202.24) 741.49 (164.76) 821.82 (363e28) 841.78 (353.71) 983.51 (358.69) 155.63 (24.11)
*p 0.038**p 0.028
IL-6 (pg/ml) 79.57 (41.34) 126.28 (56.07) 365.27 (300.67) 600.38 (484 21) 37.25 (4.95) 11.33 (9.87) 49.72 (31.50) 1.9 (0.86)**p 0 0.38
The liver biochemistry and cytokine proﬁle. Mean (SE). There are signiﬁcant differences between the anti-CD163-dex (AD) group, and the placebo (*) and HDD (**) group.
There is a signiﬁcant difference between the HDD group and placebo (#).
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5. Conclusion
In conclusion, the present study shows that treatment with anti-
CD163-dex does not adversely affect regeneration of the liver after
PHx in rats, although it reduces the inﬂammatory response judged
by inﬂammatory markers.
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